tetano
Editor, Senior Moderator
J Nanopart Res
. 2022;24(1):12.
doi: 10.1007/s11051-022-05396-5. Epub 2022 Jan 10.
Polymeric nanoparticles as therapeutic agents against coronavirus disease
Letícia Emiliano Charelli[SUP] 1 [/SUP], Gabriela Calidone de Mattos[SUP] 2 [/SUP], Ariane de Jesus Sousa-Batista[SUP] 1 [/SUP], José Carlos Pinto[SUP] 2 [/SUP], Tiago Albertini Balbino[SUP] 1 [/SUP]
Affiliations
Abstract
Nanotechnology has the potential to improve the combat against life-threatening conditions. Considering the COVID-19 scenario, and future outbreaks, nanotechnology can play a pivotal role in several steps, ranging from disinfection protocols, manufacture of hospital clothes, to implementation of healthcare settings. Polymeric nanoparticles are colloidal particles with size ranging from 10 to 999 nm, composed of natural or synthetic polymers. The versatility of polymeric-based nanoparticle engineering can provide (i) specificity, (ii) tunable release kinetics, and (iii) multimodal drug composition, making it possible to overcome common limitations encountered during traditional drug development. Consequently, these particles have been widely used as drug delivery systems against several diseases, such as cancer. Due to inherent competitive advantages, polymeric-based nanoparticles hold astonishing potential to counteract the new coronavirus disease (COVID-19). For this reason, in the present study, the latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2 are compiled and discussed. Moreover, the importance of forefront in vitro technologies - such as 3D bioprinting and organ-on-chip - to evaluate the efficacy of nanotherapeutic agents is also highlighted. Polymeric nanoparticles can be functionalized to enhance its potential as a nanotherapeutic agent. Due to its many advantages, polymeric-based nanoparticles systems are a promising approach against coronavirus disease 2019 (COVID-19).
Keywords: COVID-19; Coronavirus; Drug delivery; Nanobiotechnology; Nanomedicine; Polymer; Polymeric nanoparticles; SARS-CoV-2.
. 2022;24(1):12.
doi: 10.1007/s11051-022-05396-5. Epub 2022 Jan 10.
Polymeric nanoparticles as therapeutic agents against coronavirus disease
Letícia Emiliano Charelli[SUP] 1 [/SUP], Gabriela Calidone de Mattos[SUP] 2 [/SUP], Ariane de Jesus Sousa-Batista[SUP] 1 [/SUP], José Carlos Pinto[SUP] 2 [/SUP], Tiago Albertini Balbino[SUP] 1 [/SUP]
Affiliations
- PMID: 35035277
- PMCID: PMC8747451
- DOI: 10.1007/s11051-022-05396-5
Abstract
Nanotechnology has the potential to improve the combat against life-threatening conditions. Considering the COVID-19 scenario, and future outbreaks, nanotechnology can play a pivotal role in several steps, ranging from disinfection protocols, manufacture of hospital clothes, to implementation of healthcare settings. Polymeric nanoparticles are colloidal particles with size ranging from 10 to 999 nm, composed of natural or synthetic polymers. The versatility of polymeric-based nanoparticle engineering can provide (i) specificity, (ii) tunable release kinetics, and (iii) multimodal drug composition, making it possible to overcome common limitations encountered during traditional drug development. Consequently, these particles have been widely used as drug delivery systems against several diseases, such as cancer. Due to inherent competitive advantages, polymeric-based nanoparticles hold astonishing potential to counteract the new coronavirus disease (COVID-19). For this reason, in the present study, the latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2 are compiled and discussed. Moreover, the importance of forefront in vitro technologies - such as 3D bioprinting and organ-on-chip - to evaluate the efficacy of nanotherapeutic agents is also highlighted. Polymeric nanoparticles can be functionalized to enhance its potential as a nanotherapeutic agent. Due to its many advantages, polymeric-based nanoparticles systems are a promising approach against coronavirus disease 2019 (COVID-19).
Keywords: COVID-19; Coronavirus; Drug delivery; Nanobiotechnology; Nanomedicine; Polymer; Polymeric nanoparticles; SARS-CoV-2.